<DOC>
	<DOCNO>NCT02132637</DOCNO>
	<brief_summary>The primary purpose study compare effect double dos study drug know insulin peglispro insulin glargine participant type 2 diabetes . Participants treat 11 week , take part two study period . Each participant receive insulin peglispro one treatment period insulin glargine treatment period .</brief_summary>
	<brief_title>A Study Compare Effect Double Doses Long-acting Insulin Therapies Participants With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Have type 2 diabetes mellitus ( T2DM ) , base World Health Organization ( WHO ) classification , ≥1 year . Use type basal insulin ( except degludec ) , include onceor twicedaily human insulin neutral protamine Hagedom ( NPH ) , insulin detemir , insulin glargine . Have hemoglobin A1c ( HbA1c ) level ≤9.0 % accord central laboratory test screen . Have body mass index ( BMI ) ≤40.0 kilogram/square meter ( kg/m^2 ) . Have treat stable dos insulin least 30 day screen : Basal insulin daily dos ±30 % mean last 4 week . Doses basal insulin must 0.3 unit/kg/day 1 unit/kg/day . If metformin , thiazolidinediones ( TZDs ) , sodium glucose cotransporter 2 ( SGLT2 ) inhibitor , dipeptidyl peptidase ( DPP4 ) inhibitor , must stable dos last 30 day . Are use prandial , selfmixed , premixed insulin . Participants use prandial insulin may switch everyday ( qd ) glargine investigator judge participant still meet fast glucose requirement randomization . Are use insulin pump therapy . Have excessive insulin resistance : Defined &gt; 1.0 unit/kg/day baseline treatment . If treat sulfonylurea ( SUs ) screening , must SUs wash screen randomization . Use concomitant medication : morphine , codeine , antidiuretic , glucagonlike peptide1 ( GLP1 ) receptor agonist ( example , exenatide , exenatide weekly , lixisenatide liraglutide ) , pramlintide , use concurrently within 90 day screen . Have hypoglycemia unawareness , define confirmed laboratory test result historical episode hypoglycemia &lt; 54 mg/dL ( 3.0 mmol/L ) without symptom . Have fast hypertriglyceridemia &gt; 400 mg/dL ( &gt; 4.5 mmol/L ) screening , determine local laboratory . Have episode severe hypoglycemia ( define require assistance due neurologically disable hypoglycemia ) within 6 month entry study . Have 2 emergency room visit hospitalization due poor glucose control past 6 month . Have previous clinically significant episode ketoacidosis determine investigator ( ketone body fast without acidosis acceptable ) past 6 month . Have history renal transplantation , currently receive renal dialysis , estimate Glomerular Filtration Rate ( eGFR ) &lt; 60 milliliters/minute . Have obvious clinical sign symptom liver disease ( exclude nonalcoholic fatty liver disease ) , acute chronic hepatitis , nonalcoholic steatohepatitis , elevate liver enzyme measurement . Have active untreated malignancy , remission clinically significant malignancy ( basal cell squamous cell skin cancer ) less 5 year , increase risk develop cancer recurrence cancer opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>